London, England – April 23, 2026 – Nectero Therapeutics, a clinical-stage biotechnology company developing therapies for aneurysmal disease, released two-year outcomes data today from the company’s first-in-human (FIH) trial of their investigational Nectero EAST® System. The results were presented at Charing Cross 2026 by Dr. Andrew Holden during a session on Abdominal Aortic Aneurysm (AAA) disease management.Continue reading
Category Archives: AZBio News
CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices
New pathway cuts red tape and brings predictability to Medicare coverage for Breakthrough DevicesContinue reading
ASU’s Panchanathan to lead Phoenix Quantum Strategy
Mayor announces initiative aimed at positioning city — and its economy — at forefront of ‘next era of breakthrough technology’Continue reading
Jake Birecki Makes Space for Passion, Purpose and Play
AZBio Members are driven by their commitment to improve the lives of patients and their families. At BioMarin, part of this commitment includes sharing the stories of the people they work to serve. In the first edition of their “Making Space” series, BioMarin profiled Arizona-native Jake Birecki.Continue reading
AIRNA Joins C-Path’s Alpha-1 Antitrypsin Deficiency Consortium to Advance Innovative AATD Treatments
AIRNA, a clinical-stage company developing RNA-editing medicines with an initial focus on AATD, joins C-Path’s antitrypsin consortium upon initiation of its RepAIR1 global clinical study.Continue reading
Getting Ready for SBIR and STTR Funding Opportunities
On April 14, NIH’s Seed Fund (Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs) was reauthorized for the next five years. The reauthorization restores momentum, improves the programs, and reopens pathways for both new applicants and currently funded projects.Continue reading
Apprenti Reaches Major Milestone with USDOL Approval of National Biomanufacturing Technician Standards
[Seattle, WA] April 15, 2026 – Apprenti, the leading national intermediary for Registered Apprenticeship (RA), is proud to announce the formal approval and filing of the National Biomanufacturing Technician Standards with the U.S. Department of Labor (USDOL). Crafted under the strategic guidance of the Apprenti Life Science Advisory Board—which includes leaders from Pfizer, Merck, Thermo Fisher, and Biogen—these standards were developed in close partnership with the Life Sciences Workforce Collaborative (LSWC) and InnovATEBIO as part of a high-impact NIIMBL project. Continue reading
AZBio Member Spotlight – NuvOx Pharma
Based in Tucson, Arizona, NuvOx Pharma is working to solve one of medicine’s quieter but deeply serious problems: cellular hypoxia, or what happens when the body’s tissues don’t get enough oxygen. Their lead product, NanO2, is designed to restore that balance, and the conditions they’re targeting are anything but small.Continue reading
Seven Arizona research projects earn $100K grants from Flinn Foundation
Seven Arizona-based research teams have been awarded $100,000 grants from the Flinn Foundation as members of the 2026 Translational Seed Grants Program cohort. The new awardees represent six institutions — two from Arizona State University and one each from HonorHealth Research Institute, Mayo Clinic Arizona, Northern Arizona University, Translational Genomics Research Institute, or TGen, and University of Arizona. Barrow Neurological Institute, Black Canyon Bio, Smile Train, University of California, Davis, NAU, UCLA and Ohio State University all serve as partners on the projects, which address conditions including Valley fever, epilepsy, cleft conditions, and brain cancer.Continue reading
AZBio Member Spotlight – Bright Path Labs
Based in Mesa, Arizona, Bright Path is advancing pharmaceutical innovation by strengthening domestic manufacturing and addressing critical supply chain challenges. Through cutting-edge technology and a commitment to sustainability, the company is working to ensure patients have reliable access to essential medicines.Continue reading